Virker dødfødt hele greiene, stakkars folk som har vert med hele veien nedigjen fra 22-23kr eller hva den var oppe i.
Woulgan skulle redde verden, salget som har vert er vel stort sett vare aksjonærene selv har kjøpt, emisjonen som var, holder heller ikke lenge om det ikke er ett ess i ermet
Biotec Pharmacon - Mandatory notification of trade
(Tromsø 17. August 2018) Rolf E. Engstad, CSO of Biotec BetaGlucans has purchased 20 000 shares in Biotec Pharmacon at NOK 4.99 per share. After this transaction holds Engstad 430.774 shares and 40.000 options in Biotec Pharmacon
For further information, please contact
Børge Sørvoll
CFO
+47 952 90 187
[email protected]Ekstern link: http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=5097219&fn=release.html
Nyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180817.Cision.20180816:BIT:0614:0
Biotec Pharmacon ASA will present at LSX Nordic Conference
Biotec Pharmacon ASA (OSE:BIOTEC) will present at the LSX Nordic Conference taking place in Stockholm today, Thursday 30. August. Estimated start of the presentation will be at 14.00. Speaker will be CEO Christian Jørgensen.
Please find the presentation attached.
For further information
Børge Sørvoll
CFO
+47 952 90187
[email protected]Ekstern link: http://feed.ne.cision.com/client/waymaker1/WOLReleaseFile.aspx?id=5127337&fn=release.html
Ekstern link: http://mb.cision.com/Public/1090/2604669/b96b86a66cd8ad01.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180830.Cision.20180830:BIT:0969:0
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre 
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @Kronn (3 likes)
- @FiloD (1 likes)
Gratulerer!
Biotec Pharmacon changes management in the wound care area
(Tromsø 20 September 2018) Stuart Devine, who has been leading Biotec’s efforts
in introducing Woulgan® to the market for the last 3 years is leaving Biotec
Pharmacon after a mutual agreement.
Biotec Pharmacon has hired Mr. Finn Ketler to manage the wound care area going
forward. Finn has a long and extensive background within medical devices and
wound care. He spent 14 years in Coloplast with various roles of increasing
responsibility, amongst others managing Coloplast’s wound care division. Finn
Ketler listed the Swedish medical device start-up Vigmed at Nasdaq First North
in Stockholm as a CEO. Today Finn is acting as a Selection Committee member in
BioInnovation Institutes (BII) Incubation programme - a position of trust Finn
will continue to have. BII is a Novo Nordisk Foundation initiative.Finn Ketler is a Danish national and has a M.Sc. from Aarhus Business School.
“I would like to take this opportunity to thank Stuart for his 3 years of hard
work in developing the Woulgan business and also extend a warm welcome to Finn
on the team”, says CEO Christian Jørgensen.The transition of roles will take place over the next quarter.
For more information, please contact:
CEO Christian Jørgensen, tel +47 47 79 24 57About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. ArcticZymes develops, produces and markets enzymes of marine
origin used in molecular DNA technologies and diagnostics, representing growth
markets where rapid technological developments are creating a strong demand for
new and improved enzymesEkstern link: http://www.newsweb.no/index.jsp?messageId=459905
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180920.OBI.20180920S109
Endinger må til når noe feiles, spennende å se om Mr Ketler har nøkkelen til sukses
Det har han ikke, for å sige det mildt, så er dette et meget dårligt bytte. Trist fordi jeg trodde Jørgensen hadde bedre dømmekraft enn som så.
Utrolig at man ikke kan få ordentlige folk til å drive dette selskab.
AZ har faktisk et godt potensiale.
Devine ble jo genierklært på Hegnar da han ble ansatt. Han har ikke utrettet stort.
Jeg har fulgt lite med på Biotec siste året tiltross for at jeg har aksjer i selskapet. (kjøpt på ca kr. 7,- da dansken overtok for Lien). Hva sier største eier (Ormestad) om utviklingen?
Har inntrykk av at han er rimelig taus, bortsett fra at eg ser han poster en del på
Facebook.
Kan virke til at han har stor tillit til ledelsen, merkelig nok, etterkvart som det stadig skjer endringer uten at det ser ut til og endre noe for selskapet
ArcticZymes AS secures first supply agreement for utility of Salt Active Nuclease in Gene Therapy
(Tromsø 30. September 2018) Biotec Pharmacon ASA’s (OSE:BIOTEC) subsidiary
ArcticZymes secures its first supply agreement for the utility of Salt Active
Nuclease (SAN) in the cGMP manufacturing of viruses for gene therapy
ArcticZymes’ Novel SAN-HQ enzyme offers gene therapy and vaccine customers a
more cost effective and technically superior solution for removing contaminating
DNA during the manufacturing process of therapeutic viruses. This represents a
critical and challenging step in the manufacturing process where long
-established alternative technologies are costlier and technically suboptimal.
Cost and technical inefficiencies represent key challenges for the wider
adoption of gene therapy. ArcticZymes SAN-HQ allows customers to overcome these
hurdles in one part of the complicated workflow in the manufacturing of cGMP
grade therapeutic viruses. cGMP (current Good Manufacturing Practices) is
relevant when a drug leaves the laboratory and enters into production, where
scale, consistent quality and robustness are key requirements.The undisclosed customer is a leading pioneer in the rapidly growing gene
therapy market. Unlike traditional therapeutics, gene therapy provides realistic
opportunity to cure devastating childhood genetic diseases and cancers by using
viruses to modify DNA within a patient’s cells.Commercial value of individual deals is anticipated to be in the 1-3 MNOK range
per annum as customers lock down their large-scale cGMP manufacturing processes.
The ability to produce viruses in large-scale is a critical factor to ensure
that enough virus can be produced to support clinical trials and approved
therapeutics.“Securing our first supply agreement to support cGMP manufacturing of gene
therapy viruses via our novel technologies is a milestone for ArcticZymes. We
are excited and privileged that ArcticZymes can play a part in supporting our
customers who are pioneering gene therapy solutions to cure devastating and life
-threatening diseases.” says Jethro Holter, Managing Director ArcticZymes, AS.For more information, please contact:
CEO Christian Jørgensen, tel +47 47 79 24 57
MD ArcticZymes, Jethro Holter +47 46 85 91 45
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel
immunomodulating products, including Woulgan®, a premium priced product in the
advanced wound care market. ArcticZymes develops, produces and markets enzymes
of marine origin used in molecular DNA technologies and diagnostics.Ekstern link: http://www.newsweb.no/index.jsp?messageId=460395
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180930.OBI.20180930S4
3 Likes
Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre 
Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.
Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:
- @FiloD (1 likes)
Gratulerer!
Biotec Pharmacon ASA: Invitation to presentation of Q3 2018 results
Biotec Pharmacon presents its report for the third quarter 2018 on Thursday, 18.
October 2018. The presentation will be given by CEO Christian Jørgensen and CFO
Børge Sørvoll
The presentation starts at 08:30 CET and will be in English.
Venue: Hotel Continental, Stortingsgata 24/26, Oslo.The presentation can also be followed as a live webcast from Hegnar TV on
www.biotec.no or http://webtv.hegnar.no/presentation.php?webcastId=97451281
It will be possible to post questions through the webcast console. The interim
report for the third quarter 2018 will be available on www.newsweb.no and on the
company’s homepage, www.biotec.no from 07:00 CET on 18.Ocotober 2018.For further information, please contact:
Børge Sørvoll
CFO
+47 952 90187
borge.sorvoEkstern link: http://www.newsweb.no/index.jsp?messageId=461082
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20181011.OBI.20181011S34
Biotec Pharmacon: Results for Q3 2018
(Tromsø, October 18, 2018) Biotec Pharmacon ASA (“Biotec”, OSE: BIOTEC) reported
sales of NOK 22.1 million (14.4) in the third quarter of 2018, and a negative
EBITDA of NOK 0.2 million (-7.3). ArcticZymes generated sales of NOK 9.8 million
during the third quarter whereas Woulgan® generated sales of NOK 0.9 million.
“At the last quarterly announcement, we informed about the fluctuating purchase
pattern of our large customers especially within our enzymes business, but also
stated that we were certain it would rebound in the second half of 2018. In
third quarter, sales rebounded as we expected. Furthermore, we now have the new
commercial organization up to full speed. Outside the new cGMP customer within
gene therapy announced earlier, ArcticZymes also signed a new customer within
the molecular diagnostic area proving that our products are very competitive
within these specialized customer segments”, says CEO, Christian Jørgensen.Woulgan generated better sales than the same quarter last year, and experienced
positive developments especially in Germany despite the on-going national
discussions on reimbursement. In Germany Biotec experienced repeat orders from
existing customers as well as first orders from new customers. In the UK,
Woulgan is listed on 5 formularies with new potential clinics and formularies in
the pipeline. In general, the UK market has long lead time from the nurse’s
acceptance of the product until the product is on formularies.Biotec continues to invest in the clinical study in New York, where SBG® is used
as an adjuvant to a vaccine against the relapse of Neuroblastoma. Biotec is
encouraged by the results published in May 2018 as well as increased patient
enrolment into the study. Biotec together with the Neuroblastoma study partners
continue to evaluate the potential and timelines of this opportunityIn connection with the third quarter announcement, CEO Christian Jørgensen
states: “We had a good quarter and see positive third quarter developments in
all our business areas. We managed to register the best EBITDA result in many
quarters. As we are a small company with large customers, fluctuating order
patterns can change the quarter to quarter development, but the fundamentals of
our business and the customer reaction to our products gives us confidence in
the future of the company. We continue to manage our cash tightly and had 13%
lower spend in the first three quarters of 2018 versus the same period last
year.”The complete interim report for Q3 2018 is enclosed. The company is hosting a
presentation on October 18, 2018 at 08:30 CET at Hotel Continental,
Stortingsgata 24/26, Oslo.For additional information,
Christian Jørgensen, CEO, +47 47 79 24 57 [email protected]
Børge Sørvoll CFO, +47 95 29 01 87 [email protected]About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel
immunomodulating products, including Woulgan®, an advanced wound care product
for stalled wounds with a proprietary medicinal ingredient. ArcticZymes
develops, produces and markets recombinant enzymes of marine origin used in
molecular DNA technologies and diagnostics, representing growth markets where
rapid technological developments are creating a strong demand for new and
improved enzymeEkstern link: http://www.newsweb.no/index.jsp?messageId=461476
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20181018.OBI.20181018S5
Biotec Pharmacon: Q3 2018 Presentation
Biotec Pharmacon presents on 18 Octobert 2018 at 08:30 its interim report for the third quarter of 2018. Speaker at the presentation will be CEO Christian Jørgensen and CFO Børge Sørvoll. Please find the presentation attached.
The presentation is also available as a webcast with log-on at www.biotec.no. It will be possible to submit questions to the speaker from the webcast console
Ekstern link: http://publish.ne.cision.com//Release/ViewReleaseHtml/C3AECB49DA85D82EE0C856B0705FC7D6
Ekstern link: http://mb.cision.com/Public/1090/2647317/a9fd22558bbe9245.pdfNyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20181018.Cision.20181017:BIT:4117:0
Financial calendar
Financial calendar for Biotec Pharmacon ASA
FINANCIAL YEAR 2018
30.01.2019 - Quarterly Report - Q4
FINANCIAL YEAR 2019
30.04.2019 - Quarterly Report - Q1
15.08.2019 - Half-yearly Report
24.10.2019 - Quarterly Report - Q315.05.2019 - Annual General Meeting
This information is published pursuant to the requirements set out in the
Continuing obligations.Ekstern link: http://www.newsweb.no/index.jsp?messageId=461687
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20181022.OBI.20181022S40
Biotec Pharmacon - Mandatory notification of trade
(Tromsø 22. October 2018) Rolf E. Engstad, CSO of Biotec BetaGlucans has purchased 20 000 shares in Biotec Pharmacon at NOK 4.42 per share. After this transaction holds Engstad 450.774 shares and 40.000 options in Biotec Pharmacon
For further information, please contact
Børge Sørvoll
CFO
+47 952 90 187
[email protected]Ekstern link: http://publish.ne.cision.com//Release/ViewReleaseHtml/961CFDF743EB25F7E0C856B0705FC7D6
Nyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20181023.Cision.20181022:BIT:8312:0
Ja det er kanskje nok til og bremse fallet i aksjen en dag eller to